The company also issued a 2025 guidance that fell short of expectations, as some of the company's older drugs face ...

Bristol-Myers Squibb (BMY) to announce Q4 earnings on February 6th. Analysts expect $1.47 EPS on $11.56B revenue.

The move comes less than a year after the company attempted to save $1.5 billion through the layoff of some 2,200 employees.

Bristol Myers Squibb beat Q4 estimates with $12.34 billion revenue and $1.67 EPS. 2025 guidance lags expectations amid ...

Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical giant with a market capitalization of $120.8 billion, finds ...

Financial discipline remained a priority, with approximately $1.1 billion of the targeted $1.5 billion in savings already realized. The company has identified an additional $2 billion in savings, with ...

The 2025 forecast reflects a revenue hit of about 18% to 20% to the company's legacy portfolio from the near-term effects of generics on cancer drugs Revlimid, Pomalyst, Sprycel and Apraxane. The ...

Bullish option flow detected in Bristol Myers ( BMY) Squibb with 17,611 calls trading, 2.0x expected, and implied vol increasing over 1 point to 29.73%. May-25 67.5 calls and Aug-25 45 puts are the ...

Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s blockbuster Dupixent. Last year, BMS reported a phase 3 trial in eosinophilic ...

Bristol Myers Squibb Co. closed 1.88% below its 52-week high of $61.10, which the company reached on January 27th.

Shares in Bristol-Myers Squibb traded lower after the drug maker gave 2025 guidance that undershot expectations. Bristol expects sales of about $45.5 billion in 2025, compared with the $46.3 billion ...

Bristol-Myers Squibb was founded in 1858 and has grown to be one of today's leading global pharmaceutical companies. For over 150 years, Bristol-Myers Squibb (BMS) has been committed to "discover ...